Charity and Voluntary Sector

DUK: 4 UK charities have joined forces to urgently campaign for a potentially sight-saving drug to be made available for people with diabetic macular oedema (DMO) after the National Institute for Health & Clinical Excellence (NICE) turned down an appeal for it to be used on the NHS.
Diabetes UK, JDRF, the Macular Disease Society (MDS) and the Royal National Institute of Blind People (RNIB) are urging the manufacturer of Lucentis, Novartis, to rapidly agree a patient access scheme with the Department of Health and NICE.

 Such a scheme would reduce the cost of this treatment to the NHS and ensure the maximum number of people with DMO can benefit from the treatment without delay.
Press release & links
Implement a Building Readiness Inspection Before Reopening